BCL2
Apoptosis regulator Bcl-2
As of the edition of 20 October 2026, BCL2 (apoptosis regulator Bcl-2, UniProt P10415) has 17 drugs tested at it and 15 companies on the list, 7 on route A and 2 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P10415
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- In more than one place
- Solved structures
- 63
- Disease areas
- Cancer; Blood and lymph; Immune system; Heart and blood vessels; Skin and connective tissue; Infections; Lungs and airways; Urinary and reproductive
- Registered trials of its drugs
- 892
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 2 |
| Active | 8 |
| Went quiet | 2 |
| Stopped | 4 |
| Status not established | 1 |
| Total | 17 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Venetoclax | Marketed | Phase 4 | Ends 2032 |
| Navitoclax | Active | Phase 3 | none listed |
| Oblimersen sodium | Stopped | Phase 3 | none listed |
| Sonrotoclax | Marketed | Phase 3 | Ends 2039 |
| APG-2575 | Active | Phase 3 | none listed |
| Obatoclax | Stopped | Phase 3 | none listed |
| Pelcitoclax | Stopped | Phase 2 | none listed |
| TQB3909 | Active | Phase 3 | none listed |
| LP-118 | Active | Phase 2 | none listed |
| Rosomidnar | Went quiet | Phase 2 | none listed |
| LP-108 | Active | Phase 1 | none listed |
| VOB-560 | Stopped | Phase 2 | none listed |
12 of 17 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 7 |
| Route B | 2 |
| Engaged | 5 |
| Undetermined | 1 |
| Total on the list | 15 |
The other 12 companies at BCL2
In the product15 companies in all; 12 are not named here, and no score is.
See the 15 companies at BCL2, ranked, with the facts behind eachRequest access. Nothing is shown until you do.